N-[[2-[[(4-氰基苯基)氨基]甲基]-1-甲基-1H-苯并咪唑-5-基]羰基]-N-2-吡啶基-beta-丙氨酸 | 212322-77-5

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: N-[[2-[[(4-氰基苯基)氨基]甲基]-1-甲基-1H-苯并咪唑-5-基]羰基]-N-2-吡啶基-beta-丙氨酸
• 中文别名: 达比加群酸氰类似物
• 英文名称: 3-({2-[(4-Cyano-phenylamino)-methyl]-1-methyl-1H-benzoimidazole-5-carbonyl}-pyridin-2-yl-amino)-propionic acid
• 英文别名: 3-(2-(((4-cyanophenyl)amino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propionic acid；1-methyl-2-[N-(4-cyanophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-hydroxycarbonylethyl)-amide；N-[[2-[[(4-Cyanophenyl)amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-2-pyridinyl-beta-alanine；3-[[2-[(4-cyanoanilino)methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoic acid
• CAS: 212322-77-5
• 化学式: C₂₅H₂₂N₆O₃
• 分子量: 454.488
• InChiKey: RTTVEDNJNQCLFS-UHFFFAOYSA-N

物化性质

• 沸点：
  798.8±60.0 °C(Predicted)
• 密度：
  1.32±0.1 g/cm3(Predicted)
• 溶解度：
  二氯甲烷、甲醇

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  34
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  124
• 氢给体数：
  2
• 氢受体数：
  7

上下游信息

• 上游原料

  中文名称	英文名称	CAS号	化学式	分子量
  3-[[[2-[[(4-氰基苯基)氨基]甲基]-1-甲基-1H-苯并咪唑-5-基]羰基]吡啶-2-基氨基]丙酸乙酯	ethyl 3-(2-((4-cyanophenylamino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate	211915-84-3	C27H26N6O3	482.542

• 下游产品

  中文名称	英文名称	CAS号	化学式	分子量
  ——	1-methyl-2-[N-(4-cyanophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-[2-(methanesulphonylaminocarbonyl)-ethyl]-amide	212322-47-9	C26H25N7O4S	531.595
  ——	{2-[3-({2-[(4-Cyano-phenylamino)-methyl]-1-methyl-1H-benzoimidazole-5-carbonyl}-pyridin-2-yl-amino)-propionylamino]-ethyl}-carbamic acid tert-butyl ester	1315605-56-1	C32H36N8O4	596.689
  达比加群杂质J	methyl-3-[[[2-[[[4-[amino[[[(hexyloxy)carbonyl]imino]methyl]]phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl](pyridin-2-yl)amino]propionate	211915-00-3	C33H39N7O5	613.717

反应信息

• 作为反应物：
  描述：

  N-[[2-[[(4-氰基苯基)氨基]甲基]-1-甲基-1H-苯并咪唑-5-基]羰基]-N-2-吡啶基-beta-丙氨酸 在 盐酸 、 potassium carbonate 作用下， 反应 15.0h， 生成 达比加群杂质J
  参考文献：
  名称：

  Identification, Synthesis, and Strategy for the Reduction of Potential Impurities Observed in Dabigatran Etexilate Mesylate Processes

  摘要：

  Synthetic impurities that are present in dabigatran etexilate mesylate were studied, and possible pathways by which these impurities are formed during the manufacturing process were examined. The impurities were monitored by high-performance liquid chromatography, and their structures were determined by mass spectrometry and H-1 and C-13 NMR. Potential causes for the formation of these impurities are discussed, and strategies to minimize their formation are also described.

  DOI：

  10.1021/op500084q
• 作为产物：
  描述：

  3-[[[2-[[(4-氰基苯基)氨基]甲基]-1-甲基-1H-苯并咪唑-5-基]羰基]吡啶-2-基氨基]丙酸乙酯 在 sodium hydroxide 作用下， 以 乙醇 、 水 为溶剂， 反应 2.0h， 以96.1%的产率得到N-[[2-[[(4-氰基苯基)氨基]甲基]-1-甲基-1H-苯并咪唑-5-基]羰基]-N-2-吡啶基-beta-丙氨酸
  参考文献：
  名称：

  Identification, Synthesis, and Strategy for the Reduction of Potential Impurities Observed in Dabigatran Etexilate Mesylate Processes

  摘要：

  Synthetic impurities that are present in dabigatran etexilate mesylate were studied, and possible pathways by which these impurities are formed during the manufacturing process were examined. The impurities were monitored by high-performance liquid chromatography, and their structures were determined by mass spectrometry and H-1 and C-13 NMR. Potential causes for the formation of these impurities are discussed, and strategies to minimize their formation are also described.

  DOI：

  10.1021/op500084q

文献信息

• Disubstituted bicyclic heterocycles, the preparations and the use
  申请人：Boehringer Ingelheim Pharma KG

  公开号：US06087380A1

  公开（公告）日：2000-07-11

  New disubstituted bicyclic heterocycles of general formula R.sub.a --A--Het--B--Ar--E (I) Compounds of the above general formula I, wherein E denotes an R.sub.b NH--C(.dbd.NH)-- group, have valuable pharmacological properties, particularly a thrombin-inhibiting effect and the effect of prolonging thrombin time, and those wherein E denotes a cyano group, are valuable intermediates for preparing the other compounds of general formula I. Exemplary compounds of formula I are: (a) 1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(2-hydroxycarbonylethyl)-amide, (b) 1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(hydroxycarbonylmethyl)-amide, (c) 1-Methyl-2-[N-(4-amidino-2-methoxy-phenyl)-aminomethyl]-benzimidazol-5-yl- carboxylic acid-N-(2-pyridyl)-N-(hydroxycarbonylmethyl)-amide, and (d) 1-Methyl-2-[N-[4-(N-n-hexyloxycarbonylamidino)phenyl]aminomethyl]-benzimid azol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl) amide.

  新的二取代杂环化合物的一般公式为R.sub.a --A--Het--B--Ar--E（I）。上述一般公式I的化合物中，E代表一个R.sub.b NH--C(.dbd.NH)--基团，具有有价值的药理特性，特别是抑制凝血酶的作用和延长凝血酶时间的作用，其中E代表氰基的化合物是制备一般公式I其他化合物的有价值中间体。公式I的示例化合物包括：（a）1-甲基-2-[N-(4-氨基苯基)-氨甲基]-苯并咪唑-5-基-羧酸-N-苯基-N-(2-羟基羰基乙基)-酰胺，（b）1-甲基-2-[N-(4-氨基苯基)-氨甲基]-苯并咪唑-5-基-羧酸-N-(2-吡啶基)-N-(羟基羰基甲基)-酰胺，（c）1-甲基-2-[N-(4-氨基-2-甲氧基苯基)-氨甲基]-苯并咪唑-5-基-羧酸-N-(2-吡啶基)-N-(羟基羰基甲基)-酰胺，和（d）1-甲基-2-[N-[4-(N-己氧羰胺基)苯基]氨甲基]-苯并咪唑-5-基-羧酸-N-(2-吡啶基)-N-(2-乙氧羰基乙基)酰胺。
• Anticoagulant antidotes comprising antibodies that bind dabigatran and/or related compounds and methods of use thereof
  申请人：Van Ryn Joanne

  公开号：US08821871B2

  公开（公告）日：2014-09-02

  The present invention relates to antibody molecules against anticoagulants, in particular dabigatran, and their use as antidotes of such anticoagulants.

  本发明涉及抗抗凝剂，特别是达比加群的抗体分子，以及它们作为这类抗凝剂的解毒剂的用途。
• [EN] IMPROVED PROCESS FOR PREPARATION OF DABIGATRAN ETEXILATE AND ITS NOVEL INTERMEDIATE<br/>[FR] PROCÉDÉ AMÉLIORÉ DE PRÉPARATION D'ÉTÉXILATE DE DABIGATRAN ET SON NOUVEL INTERMÉDIAIRE
  申请人：ALEMBIC PHARMACEUTICALS LTD

  公开号：WO2013024384A1

  公开（公告）日：2013-02-21

  Provided are intermediates for preparing dabigatran etexilate i.e. isopropanol solvate of l-methyl-2-[N-(4-amidinophenyl)-aminomethyl] benzimidazol-5-yl-carboxylicacid-N-(2-pyridyl)-N-(2-ethoxy carbonyl ethyl)-amide hydrochloride of formula (Vila) and crystalline form II of l-methyl-2-[N-(4-amidinophenyl)-aminomethyl] benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-ethoxy carbonyl ethyl)-amide hydrochloride of formula (VII).

  提供了制备达比加群酯中间体的物质，即l-甲基-2-[N-(4-氨基苯基)-氨甲基]苯并咪唑-5-基-羧酸-N-(2-吡啶基)-N-(2-乙氧羰基乙基)-酰胺盐酸盐（Vila）的异丙醇溶剂化合物和l-甲基-2-[N-(4-氨基苯基)-氨甲基]苯并咪唑-5-基-羧酸-N-(2-吡啶基)-N-(2-乙氧羰基乙基)-酰胺盐酸盐（VII）的结晶形式II。
• Disubstituted bicyclic heterocycles, the preparation thereof, and their use as pharmaceutical compositions
  申请人：Boehringer Ingelheim Pharma KG

  公开号：US20030004181A1

  公开（公告）日：2003-01-02

  Disubstituted bicyclic heterocycles of general formula I Ra—A-Het-B—Ar—E (I). Compounds of general formula I, wherein E is an R b NH—C(=NH)— group, have valuable pharmacological properties, particularly a thrombin-inhibiting effect and the effect of prolonging thrombin time, and those wherein E is a cyano group, are valuable intermediates for preparing the other compounds of general formula I.

  通式为IRa—A-Het-B—Ar—E（I）的双取代的杂环化合物。通式为I的化合物中，E为RbNH—C(=NH)—基团具有有价值的药理学特性，特别是抑制凝血酶的作用和延长凝血酶时间的作用，而E为氰基的化合物则是制备通式为I的其他化合物的有价值的中间体。
• Disubstituted bicyclic heterocycles, the preparation and the use thereof as pharmaceutical compositions
  申请人：Boehringer Ingelheim Pharma KG

  公开号：US06469039B1

  公开（公告）日：2002-10-22

  New disubstituted bicyclic heterocycles of general formula Ra—A—Het—B—Ar—E  (I) Compounds of the above general formula I, wherein E denotes an RbNH—C(═NH)— group, have valuable pharmacological properties, particularly a thrombin-inhibiting effect and the effect of prolonging thrombin time, and those wherein E denotes a cyano group, are valuable intermediates for preparing the other compounds of general formula I. Exemplary compounds of formula I are: (a) 1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(2-hydroxycarbonylethyl)-amide, (b) 1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(hydroxycarbonylmethyl)-amide, (c) 1-Methyl-2-[N-(4-amidino-2-methoxy-phenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(hydroxycarbonylmethyl)-amide, and (d) 1-Methyl-2-[N-[4-(N-n-hexyloxycarbonylamidino)phenyl]aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl) amide.

  通式为Ra—A—Het—B—Ar—E的新型二取代的双环杂环化合物(I)，其中E表示RbNH—C(═NH)—基团，具有有价值的药理学特性，特别是抑制凝血酶的作用和延长凝血酶时间的作用，其中E表示氰基的化合物是制备通式I其他化合物的有价值中间体。通式I的示例化合物包括：(a) 1-甲基-2-[N-(4-氨基苯基)-氨甲基]-苯并咪唑-5-基-羧酸-N-苯基-N-(2-羟基羧乙基)-酰胺，(b) 1-甲基-2-[N-(4-氨基苯基)-氨甲基]-苯并咪唑-5-基-羧酸-N-(2-吡啶基)-N-(羟基甲基)-酰胺，(c) 1-甲基-2-[N-(4-氨基-2-甲氧基苯基)-氨甲基]-苯并咪唑-5-基-羧酸-N-(2-吡啶基)-N-(羟基甲基)-酰胺，和(d) 1-甲基-2-[N-[4-(N-正己氧羰基酰胺基)苯基]氨甲基]-苯并咪唑-5-基-羧酸-N-(2-吡啶基)-N-(2-乙氧羰基乙基)酰胺。